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tus reduction should be included as a primary or secondary endpoint in future
randomized clinical trials of investigative agents for atopic dermatitis.
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A SYSTEMATIC EVALUATION OF ORAL ANTIBIOTIC AND ISOTRETINOIN
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OBJECTIVES: To evaluate the quality of published evidence of oral antibiotic and
isotretinoin therapies in the treatment of moderate to severe acne. METHODS: A
systematic search of published literature was conducted using PubMed and Em-
base using key word “acne” and therapy names doxycycline; tetracycline; minocy-
cline; erythromycin; sulfamethoxazole-trimethoprim (SMXTMP); azithromycin;
isotretinoin; and tretinoin. Studies evaluating topical retinoids and oral antimicro-
bials were also included. No date restrictions were used in order to capture all
relevant studies. Studies were eligible for inclusion if they meet the following cri-
teria: 1) randomized or observational clinical evaluations in humans; 2) published
in English; 3) duration of 8 week period or greater; and 4) evaluated at least 5
subjects. After title and abstract review, relevant citations were obtained and re-
viewed for inclusion. Data was abstracted into a standardized data collection form
by one author and verified by another. Study quality was rated using the Jadad
scale. RESULTS: A total of 588 articles were identified, but only 164 studies met all
inclusion criteria. The mean (SD) minimum age was 14.2 (2.32) and study duration
was 19 weeks (SD39). On average the sample size per treatment arm was 92
(SD176). Study designs included: crossover (6); observational (69); randomized-
controlled trial (82), non-randomized (1) and not reported/unknown (6). The num-
ber of studies evaluating the various treatments were: azithromycin (16); doxycy-
cline (24); erythromycin (20); isotretinoin (86); minocycline (40); SMXTMP (2); and
tetracycline (47). A total of 204 studies were RCTs, with 57 (28.1%) reporting inten-
tion-to-treat and 146 (71.9%) per-protocol results. Among RCTs, the mean (SD)
Jadad score was 2.75 (1.50) for azithromycin; 2.81 (1.76) for doxycycline; 4.00 (1.04)
for erythromycin; 2.80 (1.52) for isotretinoin; 3.32 (1.35) for minocycline; and 3.57
(1.02) for tetracycline. CONCLUSIONS: In general, the quality of randomized con-
trolled trials evaluating antibiotic treatments for moderate to severe acne is vari-
able.
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OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. A tool to effectively communicate information through graphical means is
a necessity in a field where clinicians, epidemiologists, economists, and statisti-
cians interact frequently. Using data visualization techniques, we present treat-
ment patterns among patients with psoriasis. METHODS: Using 100% National
Medicare Data with Part D information for psoriasis patients over 65, who had at
least one diagnosis for psoriasis were selected for study. We identified patients
who initiated therapy with tumor necrosis factor (TNF) and non-TNF medications.
For 2 years after the initiation of biologics, we examined treatment patterns such as
switching to another TNF, a non TNF, and discontinuation. Using a processing
language, we created a data visualization tool to show how patients change their
treatment pattern after first, second and third switches. RESULTS: 2,208 psoriasis
patients initiated their therapy with a TNF agent. 7.47% switched to another TNF,
2.22% switched to a non-TNF, 53.35% discontinued their therapy and 36.96% con-
tinued their initial therapy. Among the patients who switched to another TNF,
49.70% stayed on the switched therapy, 29.70% discontinued, 20.00% switched to
another TNF and no patients switched to a non-TNF. In 2 years after TNF initiation,
6.06%of patientswhomade a second switch froman initial TNF, switched to a third
TNF. 69.70% continued their second switch, 24.24% discontinued their second TNF
and no patients switched to a non-TNF. CONCLUSIONS: Data visualization tools
can effectively help researchers visualize these complicated treatment patterns,
which can be difficult to present, especially if analyzed for subsequent years and
with various switching patterns.
SENSORY SYSTEMS DISORDERS – Cost Studies
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OBJECTIVES: To estimate the financial impact of adopting ustekinumab as an ad-
ditional psoriasis treatment option on a United States (US) health plan formulary,
while incorporating comparative evidence.METHODS: Themodel perspective was
a 1 million-member US health plan (including only direct healthcare costs). Psori-
asis prevalence and biologic penetration rates were derived from publically avail-
able US sources. Base case analysis examined increasing ustekinumab market
share from launch through 5 years, with commensurate decreases inmarket share
of other biologics. Treatment costs (adalimumab, etanercept, infliximab, and
ustekinumab) were computed using August 2011 wholesale acquisition costs and
US FDAprescribing information for induction/maintenance dosing. Responder and
non-responder cohorts were modeled based on disease response rates. Responder
cost inputs included drug acquisition/administration/monitoring/outpatient vis-
its. Non-responder cost inputs included supportive care/inpatient costs. No clini-
cally significant differences in rates of adverse events requiring treatment were
assumed. RESULTS: In each modeled year, 0.03% of the health plan population
would receive biologic treatment for moderate to severe psoriasis. Without usteki-
numab, total biologic drug budget in the base yearwas predicted to be $8.42million,
and total annual medical budget for moderate to severe psoriasis was estimated at
$9.80 million. By year 5, estimates increased by 4.7%. By adding ustekinumab,
estimated therapy budget increased by 6.3% and overall medical budget increased
by 3.7% over the course of 5 years. These estimates incorporated comparative data,
which predicted the number of disease responders increasing by 15% over the
same period. Net budget increase for all covered lives was estimated at $0.031 per
member per month by year 5. CONCLUSIONS:Model results indicated reimburse-
ment for ustekinumab may have minimal impact on a US health plan’s budget,
given the relatively small size of the eligible population. Additionally, by including
comparative evidence, results illustrated the estimated positive clinical impact of
adding ustekinumab to formulary.
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OBJECTIVES: Isotretinoin, medicine used to treat severe acne has been the subject
of various studies to investigate the relationship between therapy and psychiatric
disorders. At the same time, the demand has been growing this item in the Na-
tional Health System (SUS) which incorporated the drug since 2001 and its use is
standardized by the Clinical Protocol and Therapeutic Guidelines by SUS. The aim
of work was to quantitatively evaluate the demand Isotretinoin of in the year 2011
and the financial impact of this item in the total distributed in Component Special-
ized Pharmaceutical Services –CEAF (program for access to medicines under SUS)
METHODS: Survey demand data and distributed financial value of Isotretinoin 20
mg of 2011 in SIGAF-(Computerized Management of the State Pharmaceutical As-
sistance Minas Gerais) in relation to the total amount distributed to all items of
CEAF. RESULTS: In 2011, the demand of the Isotretinoinwas 9374 new patients, the
second-placed; iron hydroxide 100mg, 3111, budesonide formoterol 400/200mcg
was placed third with 2177. The total amount distributed was equivalent to 8715
million dollars, 8% of total expended with 196 medicines that make up the CEAF.
CONCLUSIONS: Isotretinoin was the most requested in 2011 in CEAF, three times
higher than the second and 4 times higher than the third. At the same time, spend-
ing on thismedicine is relevant, considering the percentage of the total spent on all
CEAF’smedications. This represents 11.6% of the total amount spent in the State of
Minas Gerais with the treatment of cardiovascular diseases, chronic diseasesmost
prevalent in Brazil according to WHO. Considering the known risks and the lack of
conclusive studies on other adverse effects of Isotretinoin, the results highlight the
need for closer monitoring of patients and control this medicine, in order to avoid
the rampant consumption and irrational.
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OBJECTIVES:Weight of glaucoma as a cause of blindness remains significant. Thus
the problem of drug supply of glaucoma patients is actual for health care system of
Russian Federation. We conducted 3 pharmacoeconomic studies for treatment of
open-angle glaucoma for each antiglaucoma drugs groups (eye-drops): prostaglan-
din analogues (Travatan (travoprost), Xalatan (latanoprost); carbonic anhydrase
inhibitors (CAI) (Azopt (brinzolamide), Dorzopt and Trusopt (dorzolamide)) and
combined drugs of prostoglandin analogues and beta-blocker (Duotrav
(travoprosttimolol) and Xalacom (latanoprosttimolol) to find optimal antiglau-
coma drugs from pharmacoeconomics perspective in Russia. METHODS: Cost-ef-
ficacy and budget impact analysis were used, direct costs were considered.
RESULTS: In the first studywe found that Travatan is dominant in comparisonwith
Xalatan and provide lower cost per effective glaucoma control per year per patient
– cost-efficacy ratio (CER) for Travatan was 18,092 RUB and for Xalatan 19,270 RUB.
Furthermore Travatan to Xalatan provided 1091 RUB cost saving per patient per
year. The second pharmacoeconomic study of CAIs has shown that Azopt had
benefits in terms of cost-efficacy analysis to Dorzopt and Trusopt: CER (cost of
achieving annual control for glaucoma by 1% patients) for Azopt it was 304 RUB, for
Dorzopt – 342 RUB, for Trusopt – 382 RUB. The third study has shown advantage of
Duotrav in comparison with Xalacom in terms of cost-efficacy analysis and budget
impact analysis. Duotrav had lower CER (cost per 1% of patients, for whom treat-
ment remains effective for 5 years) 1345 RUB in comparison with 1463 RUB for
Xalacom and provided 1721 RUB of cost-saving (discounted at 3%). CONCLUSIONS:
The results of conducted pharmacoeconomic studies show that Travatan, Azopt
and Duotrav are dominated drugs among alternatives in health care system of
Russian Federation for treatment of open-angle glaucoma from perspective of
pharmacoeconomic analysis.
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